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S U M M A R Y
Objectives: Our aim was to analyze a retrospective cohort of renal transplant recipients to determine the
risk factors for infections that require hospitalization.
Methods: This was a cohort study that included patients who had received kidney transplants from
January 1990 to December 2003. The statistical analysis was performed according to the distribution of
variables, and p < 0.05 was considered statistically signiﬁcant.
Results: We analyzed 366 transplants in 350 patients, of whom 161 (46%) presented with an episode of
infection requiring hospitalization. These 161 patients developed 323 infections (a median of two
infections per patient). The incidence rate was 0.46 episodes per 1000 transplant-days. Urinary tract
infection, pneumonia, bacteremia, and gastroenteritis were themost common diseases. A high incidence
of infections due to Escherichia coli and Enterococcus species, as well as Candida species, was found. By
multivariate Cox model, signiﬁcant risk factors for infections requiring hospitalization were systemic
lupus erythematosus (relative risk (RR) 4.8, 95% conﬁdence interval (CI) 1.64–14.1), cancer (RR 3.81, 95%
CI 1.05–13.7), previous renal transplant (RR 5.6, 95% CI 1.4–22.4), history of anti-rejection therapy (RR
3.2, 95% CI 1.3–8.0), and a basal serum albumin concentration < 3.5 mg/dl (RR 1.77, 95% CI 1.17–2.68).
Interestingly, dyslipidemia (RR 0.5, 95% CI 0.37–0.69) and end-stage renal disease of unknown etiology
(RR 0.5, 95% CI 0.3–0.8) were protective factors against hospitalization.
Conclusions: These data suggest that themost common infections requiring hospitalization in our cohort
were those caused by microorganisms commonly related with community-acquired infections rather
than those classically associated with immunosuppressant therapy. These ﬁndings will be useful for
reﬁning medical care.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Over the last two decades, improved immunosuppressant
regimens, better surgical techniques, and better general medical
care have contributed to improvements in the survival rate and
quality of life of transplant recipients.1 However, infections
continue to be the main causes of post-transplant morbidity and
mortality.2,3 The frequency of these complications is directly
proportional to the extent of immunosuppression and exposure to
various potential pathogens. Moreover, transplant recipients show
complex interactions between chronic immunosuppression and
the presence of risk factors such as deﬁcient nutritional status,* Corresponding author. Tel.: +52 55 54870900x2505; fax: +52 55 55133945.
E-mail address: correarotter@prodigy.net.mx (R. Correa-Rotter).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.11.004hyperglycemia, mucocutaneous barrier integrity loss, and subclin-
ical activity of viral infections (e.g., cytomegalovirus (CMV) and
hepatitis B and C viruses).4–6
Infections in transplant patients are grouped according to the
time of emergence in the post-transplant period. Infections
appearing during the ﬁrst month after the transplant are
classiﬁed as ‘early’, infections occurring between the ﬁrst and
sixth month are grouped as ‘intermediate’, and those that
emerge after 6 months are termed ‘late’.7–9 The types of
microorganism involved may differ signiﬁcantly because of the
presence of unique risk factors during these periods.4 Further-
more, it is important to remember that the severity of infection
directly affects patient survival as well as graft function and
survival.10
Because of the differences that exist in global sociodemographic
and geographic conditions, the prevalence of early and lateses. Published by Elsevier Ltd. All rights reserved.
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contemporary situation in Mexico. With an emerging economy
(13th in size and diversity worldwide), Mexico has a greater
prevalence of certain infectious diseases than developed coun-
tries.12,13 We studied the type of infection, the incidence, and the
risk factors for those infections requiring hospitalization in renal
transplant recipients, as well as the consequences of these
infections on graft function and post-transplant mortality, in a
retrospective cohort of renal transplant recipients.
2. Patients and methods
2.1. Patients and setting
This study was carried out at our tertiary-care and teaching
hospital in Mexico City, with 210 beds, an 18-bed intensive care
unit, and a 28-bed emergency room. We included in this cohort
all patients who underwent renal transplantation at this
institution from January 1990 to December 2003 and who gave
written informed consent. Data were obtained from the
database of the Department of Transplantation, and the results
of patient cultures were obtained or conﬁrmed from the
database of the Laboratory of Clinical Microbiology. After renal
transplantation, the patient follow-up included three visits per
week during the ﬁrst month, two visits per week in the second
month, and one visit per week during the third month. After this
period, the patients came to the outpatient clinic once a month,
from the fourth to the twelfth month, and every three to four
months thereafter.
From 1990 to 2001, the standard immunosuppression protocol
included cyclosporine, azathioprine, and prednisone; from 2001 to
the present day, the protocol has included tacrolimus, mycophe-
nolate mofetil, and prednisone. The prophylaxis protocol during
the ﬁrst 3 months after transplantation included trimethoprim–
sulfamethoxazole 800/160 mg once daily (QD) and acyclovir
400 mg QD, as well as intravenous (IV) cefuroxime 750 mg (three
doses) for surgical prophylaxis. Additionally, patients who had a
positive tuberculin skin test and no evidence of active tuberculosis
received isoniazid 300 mg QD for 6 months. Finally, the standard
anti-rejection treatment included methylprednisolone (12 mg/kg
IV QD for 3 days).
We analyzed the cases of all renal transplant recipients who
required hospitalization due to an infectious disease. All the
cases were patients admitted to hospital for an episode of
infection. We excluded from the analysis those patients who had
an infection immediately after transplantation that delayed
their hospital discharge. The following variables were collected:
age at time of transplantation (continuous), gender (binary:
female or male), cause of end-stage renal disease (ESRD), type of
donor (categorical: deceased donor, live related donor, or live
unrelated donor), transplant number (categorical: ﬁrst or
second), histocompatibility by number of haplotypes (categori-
cal: zero haplotypes, one haplotype, and two haplotypes),
immunosuppressant therapy at the time of infection (categori-
cal: tacrolimus, cyclosporine and without calcineurin inhibitor),
use of induction therapy or anti-rejection therapy 30 days prior
to infection (binary: yes or no), surgical complications (binary:
yes or no), and associated co-morbidities (binary: yes or no),
including arterial hypertension, dyslipidemia (hypercholester-
olemia, hypertriglyceridemia or both), hypoalbuminemia (a
basal serum albumin concentration <3.5 mg/dl), autoimmune
disease, diabetes mellitus, cancer, heart disease, and liver
disease. All co-morbidities included had been diagnosed at
the time of the transplant. Variables that were evaluated in
relation to the infections were: type of infection (according to
the organ system involved and its possible relationship withhospitalization) and type of microorganism. Infections were
classiﬁed according to the post-transplant period as ‘early’ (<1
month), ‘intermediate’ (1–6 months) or ‘late’ (>6 months).
Cases of pneumonia were diagnosed on a clinical basis, and
the etiology was conﬁrmed by culture (blood, sputum,
bronchoscopy aspirate, or bronchial lavage) or antigen detection
in body ﬂuids. Cases of systemic infection were deﬁned as: (1)
primary bacteremia, when the patient had at least one or two
positive blood cultures for a microorganism, evidence of
systemic inﬂammatory response syndrome (SIRS), and no
evidence of a primary infection; in the case of coagulase-
negative staphylococci (CoNS); when the patient had two
positive blood cultures taken from different anatomical sites
and a clear clinical response after administration of speciﬁc
antimicrobial therapy; (2) secondary bacteremia, when the
patient had positive blood cultures for a microorganism
recovered from the primary source as well. We considered
the cause of gastrointestinal complications to be infectious in:
(1) cases of patients with acute diarrhea and SIRS, as well as a
signiﬁcant pathogen in the stool tests (Salmonella sp, Shigella sp,
Campylobacter sp, Aeromonas sp, Vibrio sp, Clostridium difﬁcile,
Entamoeba histolytica, and Giardia intestinalis, among other
common pathogens); (2) cases of patients with clinical
gastrointestinal manifestations, negative stool tests, and signiﬁ-
cant clinical improvement after therapy with IV ﬂuids and IV
quinolones, and in whom certain gastrointestinal side-effects of
immunosuppressant therapy (including mycophenolate mofetil)
were ruled out because reduction of the drug dosage did not
modify the acute diarrhea. Infections of the urinary tract (UTI),
in the soft-tissue and skin structures, and in the abdomen were
diagnosed by standard procedures.
To assess the impact of the infection on graft function, the
serum creatinine concentration was measured at the following
points: at the moment of the lowest serum concentration during
the post-transplant period and prior to infection, over the course of
the hospital stay and treatment of the infection, and upon hospital
discharge.
2.2. Statistical analysis
Depending on the distribution, results are expressed as
mean  standard deviation or median with range. For categorical
data, comparisons between groups were performed by Chi-square
test. One-way analysis of variance (ANOVA) or the t-test was used for
normally distributed data, and the non-parametric Kruskal–Wallis or
Mann–Whitney U-tests were used for non-normally distributed
variables. The incidence of infections was reported as episodes per
1000 transplant-days. We also analyzed the survival of patients using
the Kaplan–Meier method. For this purpose the population was
divided into two groups: cases of infection requiring hospitalization
and cases not requiring hospitalization; comparison between the
groups was performed by log rank test. The time of initiation was the
renal transplant date and patients were then followed until last
outpatient clinic visit or death. Patients who died outside of the
hospital were also censored for the analysis. Univariate and
multivariate Cox models were used to evaluate risk factors for
hospitalization, as well as for mortality. The variables included in the
Cox model were: age at time of transplantation (continuous), male
gender (binary: female or male), cause of ESRD (unknown etiology
and primary glomerulonephritis), co-morbidities (diabetes mellitus,
systemic lupus erythematosus (SLE), hypoalbuminemia, cancer, liver
disease, and dyslipidemia), previous renal transplant, deceased donor
transplant, zero haplotype match, history of anti-rejection therapy,
administration of cyclosporine A or tacrolimus, and history of surgical
complications. All p-values were two-tailed, and p < 0.05 was
considered statistically signiﬁcant.
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Figure 1. Description of the cohort of renal transplant recipients, January 1990 to
December 2003. y(A) 40 patients had incomplete information in their medical
records, although they completed clinical follow-up and their current clinical status
was known; (B) 13 patients had incomplete clinical follow-up and their current
clinical status was not known; (C) ﬁve patients had incomplete clinical follow-up
and were known to have died outside our hospital.
Table 1
Demographics, underlying diseases, and risk factors for infection in renal transplant re
Characteristic Total (n=350) In
Age, mean SD 37.9611.4 38
Gender (%)
Male 155 (44.3) 88
Etiology ESRD (%)
Unknown etiology 172 (49.1) 60
Primary glomerulonephritis 47 (13.4) 20
Metabolica 31 (8.9) 18
Systemic lupus erythematosus 30 (8.6) 24
Congenital 30 (8.6) 14
Obstructive 23 (6.6) 15
Hypertension 14 (4) 9
Other 3 (0.8) 1
Co-morbidities (%)
Hypertension 270 (77.1) 12
Dyslipidemia 147 (42) 55
Hypoalbuminemia 113 (32.3) 76
Autoimmune disease 39 (11.1) 16
Diabetes 28 (8) 25
Cancer 25 (7.1) 20
Heart disease 15 (4.3) 11
Liver disease 14 (4) 11
Transplant number (%)
1 334 (95.4) 14
2 16 (4.6) 12
Type of transplant (%)
Deceased donor 74 (21.1) 51
Live related donor 258 (73.7) 10
Live unrelated donor 18 (5.2) 9
Histocompatibilityb
0 125 (35.7) 71
1 174 (49.7) 75
2 51 (14.6) 15
Immunosuppression (%)
Cyclosporine A 254 (72.6) 11
Tacrolimus 41 (11.7) 27
Otherc 55 (15.7) 15
Anti-rejection therapy (%) 42 (12) 30
Induction therapy (%) 29 (8.3) 18
Surgical complication (%) 66 (18.9) 41
SD, standard deviation; NS, not signiﬁcant; ESRD, end-stage renal disease.
a Diabetes mellitus and hyperuricemic nephropathy.
b Histocompatibility: 0= zero haplotypes; 1=one haplotype; 2 = two haplotypes.
c Immunosuppression without calcineurin inhibitor: (1) rapamycin, azathioprine a
prednisone alone.
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3.1. Demographics and clinical characteristics
We performed a retrospective analysis of this cohort of renal
transplant recipients from January 1990 to December 2003. During
the study period, 439 renal transplants were carried out in 408
patients; however complete clinical information was available for
only 366 transplants (83.4%) in 350 patients (85.8%), with amedian
follow-up of 2005 days (range 30–5210 days). Fifty-eight patients
(14.2%) were excluded from further analysis for the reasons
outlined in Figure 1.
The mean  standard deviation age of the cohort was
37.96  11.4 years and 55.7% were female (195 patients). The causes
of ESRD, associated co-morbidities, characteristics of renal grafts, and
immunosuppressant therapy are described in Table 1. Themajority of
the patients (95.4%) had undergone their ﬁrst renal transplant, with a
large proportion receiving the kidney from a living related donor; in
this group, the majority shared one haplotype. Triple immunosup-
pressant therapy was used in 81.1% of the patients (n = 284) and
included steroids, azathioprine (or more recently mycophenolate
mofetil), and a calcineurin inhibitor, mainly cyclosporine A (72.5%).cipients
fected (n=161) Not infected (n=189) p-Value
.4111.8 37.511.1 NS
(54.7) 67 (35.4) <0.001
(37.3) 112 (59.3) NS
(12.4) 27 (14.3) NS
(11.2) 13 (6.9) <0.001
(14.9) 6 (3.2) NS
(8.7) 16 (8.5) NS
(9.3) 8 (4.2) NS
(5.6) 5 (2.6) NS
(0.6) 2 (1.0) NS
7 (78.9) 143 (75.7) NS
(34.2) 92 (48.7) 0.004
(47.2) 37 (19.6) <0.001
(9.9) 12 (6.3) NS
(15.5) 14 (7.4) 0.012
(12.4) 5 (2.6) 0.028
(6.8) 4 (2.1) NS
(6.8) 3 (1.6) 0.012
9 (92.5) 185 (97.9) 0.034
(7.5) 4 (2.1) 0.007
(31.7) 23 (12.2) <0.001
1 (62.7) 157 (83.1) NS
(5.6) 9 (4.7) NS
(44.1) 54 (28.6) 0.001
(46.6) 99 (52.4) NS
(9.3) 36 (19.0) NS
9 (73.9) 135 (71.4) NS
(16.8) 14 (7.4) NS
(9.3) 40 (21.2) NS
(18.6) 12 (6.3) <0.001
(11.2) 11 (5.8) NS
(25.5) 25 (13.2) 0.001
nd prednisone, (2) azathioprine and prednisone, (3) azathioprine alone, and (4)
Table 2
Description of 323 episodes of infection diagnosed in 161 renal transplant recipients hospitalized from 1990 to 2003
Anatomic location n=323 (%) Anatomic location n=323 (%)
Genitourinary, n (%) 161 (49.8) Systemic, n (%) 36 (11.2)
Urinary tract infection 156 Primary bacteremia 20
Renal abscess 3 Systemic CMV diseaseb 7
Epididymitis 1 Sepsis 6
Prostatitis 1 Systemic cryptococcosis 1
Respiratory tract, n (%) 42 (13.0) Varicella 2
Pneumonia 31 Digestive tract, n (%) 28 (8.7)
Acute sinusitis 6 Gastroenteritis 20
Pharyngitisa 2 Esophagitis 4
Pulmonary tuberculosis 2 Stomatitis 2
Mastoiditis 1 CMV colitis 1
Other sites, n (%) 21 (6.5) CMV gastritis 1
Cholangitis 7 Skin, bone, and joints, n (%) 35 (10.8)
Tenckhoff-associated peritonitis 5 Cellulitis 15
CMV hepatitis 4 Herpes zoster 11
CMV chorioretinitis 1 Surgical wound infection 3
Empyema 1 Tunnelitis of peritoneal catheter 3
Pancreatic abscess 1 Septic arthritis 1
Brain abscess 1 Osteomyelitis 1
Pelvic abscess 1 Erysipelas 1
CMV, cytomegalovirus.
a Hospitalized for dyspnea, dysphagia and angioedema and associated with group A Streptococcus spp.
b Positive antigenemia and evidence of systemic inﬂammatory response syndrome.
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induction therapy with anti-CD25 antibodies was administered to 29
patients (8.3%).
Sixty-six of the 350 patients developed surgical complications
(18.9%), including ureterovesical stenosis (n = 20), perirenal hema-
toma (n = 13), ureterovesicalﬁstula (n = 9), lymphocele (n = 9), renal
artery stenosis (n = 5), surgical wound infection (n = 3), graft artery
thrombosis (n = 2), graft venous thrombosis (n = 2), sigmoid injury
(in patients with multiple previous pelvic procedures) (n = 2), and
abdominalwall hematoma (n = 1). A comparison of the frequency of
surgical complicationsbetween the twogroups showeda signiﬁcant
predominance among the infected patients (p< 0.001; see Table 1).
Six patients with vascular thrombosis were excluded from the
surgical complicationsgroupdue to the thrombosis beingassociated
only with a deﬁciency of protein C.
3.2. Infections and microbiology
Of the 350 patients analyzed, 161 (46%) were hospitalized
because of infection and 189 (54%) were never hospitalized due to[(Figure_2)TD$FIG]Figure 2. Incidence rate and percentage of episodes of infection in the cohort of renal tra
represents the incidence rate in episodes per 1000 transplant-days; the black, white ainfection. Among the 161 patients hospitalized for infection, there
was a total of 323 hospitalizations (a median of two infections per
patient with a range of 1–10). Analysis of the cohort revealed the
most common infections to be UTI, pneumonia, bacteremia, and
gastroenteritis. Table 2 shows a complete description of all the
episodes of infection that required hospitalization. The incidence
rate was of 0.46 episodes per 1000 transplant-days, with a
signiﬁcant increase since 2001, a change that was primarily
attributable to increased numbers of early and intermediate
infections (Figure 2), as well as an increase in the diagnosis of all
infections (Figure 3, A–D). During this biennial period (2002–
2003), tacrolimus was used in 75% of the patients in comparison
with 24.2% during the prior period (odds ratio (OR) 9.2, 95%
conﬁdence interval (CI) 4.4–20.2). The use of mycophenolate
mofetil was not associated with a higher risk of infection in
comparison with the use of azathioprine. We found no other risk
factors associated with infection that changed over time.
In the case of episodes of UTI, we only included patients who
had a symptomatic post-transplantation UTI (acute cystitis or
pyelonephritis) and who required medical care in the hospital.nsplant recipients in Mexico, January 1990 to December 2003. The continuous line
nd gray bars represent the percentage of infections.
[(Figure_3)TD$FIG]
Figure 3. Distribution of episodes of infection over time in the cohort of renal transplant recipients, January 1990 to December 2003. Panel A is UTI, showing a predominance
of early and intermediate hospitalizations from 2001 onwards; similar results are seen in panel B (pneumonias), panel C (other infections: all except UTI and pneumonias),
and panel D (all infections: including UTI and pneumonia).
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in the intermediate period (22.4%), and 67 in the late period
(42.9%). Of the 156 episodes of UTI, 86 (55.1%) occurred in males
and 70 (44.9%) in females (p < 0.001); during the early period there
were 26 male and 17 female cases (p = 0.004), in the intermediate
period there were 17 and 10 cases, respectively (p = 0.011), and in
the late period, there were 40 and 46 cases, respectively
(p = 0.107). Escherichia coli was isolated from 72 cases (46.2%)
and Candida sp from42 (26.9%); the latter patients received speciﬁc
therapy (ﬂuconazole IV in 40 patients and amphotericin B IV in
two), and all of them showed signiﬁcant clinical improvement.
There were 31 cases of pneumonia that required hospitaliza-
tion; 11 were diagnosed in the ﬁrst period (35.5%), four in the
second (12.9%), and 16 in the third (51.6%). Cases of pneumonia
diagnosed during the ﬁrst period were one case of CMV
pneumonitis, one of Legionella pneumophila, one of Pseudomonas
aeruginosa, one of Serratia, and two cases of E. coli; ﬁve cases were
culture-negative. In two of the further cases of pneumonia
diagnosed during the second and third periods, one was caused
by L. pneumophila and the other by Pneumocystis jirovecii. During
the third period, there were two cases of pulmonary tuberculosis
and two cases of acute severe pharyngitis associated with group A
Streptococcus with dyspnea, dysphagia, and angioedema. Finally,
three and 11 cases of pneumonia were culture-negative during the
second and the third periods, respectively.
There were 20 cases of primary bacteremia; the majority were
caused by Gram-negative bacteria and four were caused by CoNS.
Additionally, there were 16 cases of secondary bacteremia, nine
associated with UTI, ﬁve with acute cholangitis, one with a central
venous catheter, and onewith cellulitis. Finally, six further patients
were hospitalized because of sepsis, all with blood cultures
positive for Gram-negative or Gram-positive bacteria (predomi-
nantly Enterococcus sp and E. coli).During the study period, 20 cases of gastroenteritis requiring
hospitalization (patients with acute diarrhea and SIRS) were
diagnosed; 18 (90%) occurred during the third period and two in
the second (10%). Of these patients, only four had a conﬁrmatory
result: one case each of Shigella, Salmonella, Clostridium difﬁcile-
associated disease, and E. histolytica. The main microorganisms
identiﬁed in the 323 episodes of infection are shown in Table 3.
Only 17 episodes of CMV infectionwere seen in 17 patients who
required hospitalization (5.3%): seven with systemic CMV disease
(SIRS and positive antigenemia), four with hepatitis (biopsy), two
with esophagitis (biopsy), and one each with colitis (biopsy),
gastritis (biopsy), pneumonitis (biopsy) and chorioretinitis (reti-
noscopy) (see Table 2). Since August 1997, patients have received
pre-emptive therapywith ganciclovir guided by the determination
of pp65 antigenemia in high-risk patients (donor positive/recipient
negative (D+/R)), while patients at intermediate or low risk have
been clinically monitored and treated upon symptom develop-
ment (deferred treatment). The majority (90%) of this cohort was
composed of intermediate and low risk populations for CMV
infection, and only 9% of them were high-risk patients (D+/R).
From the beginning of the study to July 1997 (91 months) there
were seven cases, and in the following period of August 1997 to the
end of the study (77 months) there were 10 cases (p = 0.940), all of
which occurred in patients at high risk. Of the 17 episodes of CMV
infection, ﬁve occurred in the early period (29.4%), seven in the
intermediate period (41.2%), and ﬁve in the late period (29.4%).
The etiologic diagnosis was determined in 266 of the 323
episodes (82.4%). In 57 episodes (17.6%), all appropriate cultures
taken resulted negative; these included: pneumonia (n = 18), UTI
(n = 17), acute gastroenteritis (n = 16), acute sinusitis (n = 1), acute
cellulitis (n = 1), acute prostatitis (n = 1), acute mastoiditis (n = 1),
acute epididymitis (n = 1), and erysipelas (n = 1). Among the UTI
cases, 11 had received prior antibiotics and ﬁve men with a likely
Table 3
Mainmicroorganisms identiﬁed in 323 episodes of infection diagnosed in 161 renal
transplant recipients hospitalized from 1990 to 2003
Microorganism n (%)
Gram-positive bacteria (%) 71/274 (25.9)
Enterococcus spa 38/274 (13.8)
Staphylococcus aureus 12/274 (4.4)
Mycobacterium tuberculosis 3/274 (1.1)
Streptococcus pneumoniae 2/274 (0.7)
Clostridium difﬁcile 1/274 (0.4)
Clostridium perfringens 1/274 (0.4)
Otherb 14/274 (5.1)
Gram-negative bacteria (%) 152/274 (55.5)
Escherichia coli 99/274 (36.2)
Pseudomonas aeruginosa 9/274 (3.3)
Legionella pneumophila 2/274 (0.7)
Otherc 42/274 (15.3)
Fungi (%) 51/274 (18.6)
Candida spd 42/274 (15.3)
Cryptococcus neoformans 2/274 (0.7)
Aspergillus terreus 2/274 (0.7)
Pneumocystis jirovecii 1/274 (0.4)
Othere 4/274 (1.5)
a Enterococcus faecium, Enterococcus faecalis, Enterococcus avium and Enterococcus
hirae.
b Staphylococcus epidermidis, Streptococcus spp, Corynebacterium jeikeium, Nocar-
dia asteroides and group A Streptococcus.
c Citrobacter, Klebsiella pneumoniae, Serratia, Morganella, Salmonella typhi,
Enterobacter, Proteus mirabilis, Shigella, Stenotrophomonas maltophilia, Branhamella
catarrhalis, Aeromonas sp, and Acinetobacter sp.
d Candida albicans, Candida glabrata, Candida tropicalis, Candida krusei and
Candida parapsilosis.
e Trichosporon beigelii.
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improved after treatment with quinolones.
3.3. Risk factors for infections requiring hospitalization
As a result of the univariate analysis, variables found to be
signiﬁcantly associated with the development of infections
requiring hospitalization were: male gender, ESRD secondary to
primary glomerulonephritis, diabetes mellitus, SLE, hypoalbumi-
nemia (a basal serum albumin concentration <3.5 mg/dl), cancer
(history or current active disease), liver disease, previous renal
transplant, deceased donor transplant, zero haplotype match,Table 4
Description of the characteristics of renal transplant recipients who died because of an
Gender Age Co-morbidities at
the time of infection
Haplotypea Infections
M 21 Hypertension, gout 0 Bacteremia, pneumo
M 47 Systemic lupus
erythematosus, ovarian cancer
0 Peritoneal tuberculo
M 40 Congestive heart failure 1 Sepsis
F 51 Hypertension,
diabetes, dyslipidemia
0 Sepsis, pneumonia,
UTI, esophagitis
M 48 Hypertension, diabetes 1 Pneumonia,
UTI, bacteremia
M, male; F, female; TAC, tacrolimus; CyA, cyclosporine A; UTI, urinary tract infection.
a Haplotypes: 0= zero haplotypes, 1 =one haplotype, 2 = two haplotypes.history of anti-rejection therapy, and history of surgical complica-
tions. After analysis using the multivariate Cox model, the
increased risk remained associated with: SLE (relative risk (RR)
4.8, 95% CI 1.64–14.1), cancer (RR 3.81, 95% CI 1.05–13.7), previous
renal transplant (RR 5.6, 95% CI 1.4–22.4), history of anti-rejection
therapy (RR 3.2, 95% CI 1.3–8.0), and a basal serum albumin
concentration <3.5 mg/dl (RR 1.77, 95% CI 1.17–2.68). In contrast,
dyslipidemia (RR 0.5, 95% CI 0.37–0.69) and ESRD of unknown
etiology (RR 0.5, 95% CI 0.3–0.8) were found to be signiﬁcant
protective factors against the development of an infection.
3.4. Impact of the infections on mortality and renal function
During the study period, 13 patients died: ﬁve of the 161
(3.1%) infected patients and eight of the 189 (4.2%) patients
without infection. The latter patients all died in the late period
of transplantation (six patients died because of ischemic heart
disease, one because of disseminated cancer from an unknown
primary, and one because of ovarian cancer). Table 4 shows the
most important characteristics of the infected patients who died
as a consequence of an infectious process. A Kaplan–Meier
analysis to estimate the difference in survival between patients
hospitalized and not hospitalized for infection showed a non-
signiﬁcant statistical difference (Figure 4). Moreover, univariate
and multivariate Cox regression analyses were performed to
determine possible factors associated with mortality in our
cohort. The variables analyzed were age, gender, etiology of
ESRD, co-morbidities (diabetes mellitus, SLE, hypertension,
cancer, and cardiovascular diseases), immunosuppression,
surgical complications, histocompatibility, and infections re-
quiring hospitalization. Results showed an increased mortality
risk in patients with a diagnosis of diabetes (RR 3.8, 95% CI 1.19–
12.5; p < 0.001) and a reduced mortality risk in patients
with dyslipidemia (RR 0.6, 95% CI 0.49–0.78; p = 0.024).
Infections requiring hospitalization were not associated with
an increased risk of mortality (RR 1.1, 95% CI 0.3–3.89; p = not
signiﬁcant).
A signiﬁcant increase in serum creatinine concentration (as
evidence of renal damage) upon hospital admission was observed
in 41 out of 161 patients (25.5%) with infections. Only 26 of the 41
patients (63.4%) showed a recovery of the serum creatinine
concentration by the time of discharge, while the remaininginfection
Period Microorganisms Anti-rejection
therapy
Immuno-
suppression
nia Early Enterococcus faecalis
Staphylococcus aureus
Aspergillus terreus
Yes TAC
sis Early Mycobacterium tuberculosis No CyA
Early Escherichia coli
Enterococcus faecium
Clostridium perfringens
Enterococcus avium
Yes CyA
Intermediate Candida glabrata
Candida krusei
Pseudomonas aeruginosa
cytomegalovirus
No CyA
Late Escherichia coli
Legionella pneumophila
Enterococcus faecium
Staphylococcus aureus
Pseudomonas aeruginosa
No CyA
[(Figure_4)TD$FIG]
Figure 4. A Kaplan–Meier analysis shows the difference in survival between
patients hospitalized and not hospitalized for infection. Data for survival were
right-censored for those who lost their graft during follow-up (32 patients) and for
those patients who later died (13 patients).
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them required renal replacement therapy.
4. Discussion
Our data show that in this cohort of renal transplant patients,
the most common infections leading to hospitalization were UTI,
pneumonia, bacteremia, and gastroenteritis. These results appear
comparable with data published by Singh in 2003.13 Mexico is an
upper middle-income country with a gross domestic product
(GDP) per capita of US$ 13 900 in 2009, withmore than 100million
inhabitants, which by population size makes it the third largest
country in the Western hemisphere.14 Mexico has been facing an
epidemiological transition, characterized by a population health
proﬁle that has evolved from one of high mortality rates and
infectious diseases (typical of poor countries) to one in which
mortality rates are low and non-communicable diseases cause the
majority of deaths (typical of wealthy countries).
The average incidence rate of infections leading to hospitaliza-
tion was 0.46 episodes per 1000 transplant-days, similar to other
recent reports.4,15 Interestingly the incidence rate of infections
showed a signiﬁcant increase during the last biennial period
(2002–2003). After a more detailed analysis, this increase was
found to be primarily attributable to an increase in the number of
episodes of infection occurring during the early and late periods
(Figures 2 and 3). This phenomenon could be a result of the more
intensive use of tacrolimus during the second part of the study
period, in spite of the ﬁndings of a meta-analysis done byWebster
et al., where no signiﬁcant difference was detected in the risk for
developing infections among patients using different calcineurin
inhibitors.16 In our study, a comparison of mycophenolate mofetil
with azathioprine did not show any difference in the risk of
developing infections. It is, however, well known that the
combination of tacrolimus andmycophenolate mofetil signiﬁcant-
ly increases the incidence of BK virus;17 however no screening for
this infection was carried out at our center before 2003.
UTIs have been the most common infections after renal
transplantation in different transplant programs worldwide, with
frequencies ranging from 30% to 60% during the ﬁrst year post-
transplantation.18,19 Recently, our group reported a similar rate of
35.8%.20 In this cohort, we recorded 156 episodes of UTI (48.3%),
the majority of which were secondary to common bacteria (E. coli
and Enterococcus faecalis, among others), with only 42 episodes
found to be caused by fungi (Candida sp). This ﬁnding appears
relevant, since we only included patients with symptomatic post-transplantation UTIs (acute cystitis or pyelonephritis) and SIRS,
and all these patients required medical care in the hospital
according to the Infectious Diseases Society of America (IDSA)
guidelines.21 Another interesting ﬁnding was the increased
frequency of UTI in men during the ﬁrst two periods, which could
be inﬂuenced by a selection bias (patients who required
hospitalization), since women are commonly at higher risk for
UTI.18–20 Nevertheless, this ﬁnding deserves more attention in
clinical research in the future.
Our data showed a frequency of 13.0% for respiratory tract
infection, similar to other recent studies.22,23 However, among the
31 pneumonias reported, only eight cases (25.8%) were caused by
opportunistic microorganisms (three Mycobacterium tuberculosis,
two L. pneumophila, one CMV, one P. aeruginosa, and one P.
jirovecii). It is of note that in 18 of 31 cases of pneumonia (58.1%),
no etiologic diagnosis could be made, a fairly common problem
among cases of community-acquired pneumonia worldwide.3,24
The main observations derived from these ﬁndings are: ﬁrst, that
the majority of the episodes of pneumonia were related to
community-acquired pathogens rather than classic opportunistic
organisms associated with immunosuppression,13,24 and second,
that although the incidence rate of pulmonary tuberculosis has
remained relatively high in Mexico,11,12 the number of cases of
tuberculosis in this cohort was small; this ﬁnding could be
explained by the strict scrutiny applied to all donors and recipients
accepted for renal transplantation at our institution.25
During the study period there were 36 episodes of systemic
infection (11.2%), and of these, 20 episodes were diagnosed as
primary bacteremia (6.2% of the 323 episodes of infection). Veroux
et al., in Italy showed a frequency of bacteremia of about 35% in a
series of 245 renal transplant recipients.26 In contrast, other groups
have shown lower incidences, such as that of Silva et al. in Brazil
who reported a frequency of 5.6% in a series of 3308 patients27 and
Linares et al. in Spain who showed a frequency of only 4.8%.28
Gastrointestinal infections have remained the diseases with the
highest morbidity and mortality in Mexico.12,14 Our results
showed that gastrointestinal infections were the third leading
cause of hospitalization following transplantation. Moreover,
gastrointestinal complications are recognized as common post-
transplant events;29 however, in transplant recipients it is
necessary to distinguish between infections and the side-effects
of immunosuppressants.29,30 In this study, only 20% of the cases
were conﬁrmed by detection of a signiﬁcant pathogen in the stool
samples, but in all of them the majority of the speciﬁc pathogens
were excluded and certain side-effects of the immunosuppressant
therapy (includingmycophenolatemofetil)were ruled out because
a reduction in drug dosage did not modify the acute diarrhea.
Nevertheless, these patients showed signiﬁcant clinical improve-
ment with IV ﬂuids and quinolones. Furthermore, there were very
few patients whomerited a colonoscopy to rule out CMV, since the
vast majority showed clinical improvement with the prescribed
therapy.
Among the most common infections in the renal transplant
recipient population, CMV infections are major causes of severe
complications. Our results showed a low frequency of hospitaliza-
tions due to CMV (5.3%), as our renal transplant population was
dominated by patients with low or intermediate risk for CMV and
only 9% were high-risk patients; from these patients, approxi-
mately 1% developed CMV disease, as has been reported recently
by others.31,32 As a consequence, none of the patients received any
prophylaxis or pre-emptive therapy for CMV at our hospital before
August 1997. Since then, a pre-emptive therapy strategy, guided by
pp65 antigenemia, has been used regularly for high-risk patients
(D+/R), while patients at intermediate or low risk are clinically
monitored and treated upon symptom development (deferred
treatment).31,33,34 Our data showed no difference in the number of
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commencement of the program for the early detection of CMV
infection and preemptive therapy.
Regarding parasitic infections, we have regularly carried out
standard pre-transplant evaluation and post-transplant follow-up
looking for serum markers (antibodies for Toxoplasma gondii) or a
stool examination following standard international recommenda-
tions.3,35 Surprisingly, in our study only one patient was
hospitalized because of acute colitis secondary to E. histolytica
occurring during the late period, despite the prevalence of
intestinal parasites in the general population in Mexico ranging
from 0.2% in temperate areas up to 27.1% in tropical zones.36
Although, Strongyloides stercoralis is one of themost important and
dangerous parasites reported in transplant recipients,37 only a few
cases have been detected in renal transplant recipients in
Mexico.38 Although other parasite infections such as giardiasis,
malaria and Chagas disease are common in the general population
in this part of the world,39 we did not ﬁnd any case in this cohort.
Moreover, recently our group did a multicenter cross-sectional
study to determine the seroprevalence of Chagas disease among
386 renal transplant recipients, and only four patients showed
positive results without clinical evidence of disease (unpublished
data).
Prior diagnosis of SLE or cancer, previous renal transplant,
history of anti-rejection therapy, and hypoalbuminemia at the
time of the infection were clearly associated with an increased risk
of hospitalization for infections, all of which share the common
characteristic of a great degree of immunosuppression.40–46 Of
note was the ﬁnding that dyslipidemia was less common in
patients with infections leading to hospitalization; this ﬁnding
could be attributed to a lesser degree of malnutrition among renal
transplant recipients with dyslipidemia. An analysis of the United
States Renal Data System (USRDS) data revealed that patients with
post-transplant obesity presented a lower risk of infection.47 A
second explanation could be the use of statins in a large proportion
of patients with dyslipidemia, which has been strongly associated
with a reduction in the risk of hospitalization for sepsis in patients
with chronic kidney disease.48,49 Furthermore, Potena et al.
demonstrated that ﬂuvastatin inhibition of 3-hydroxy-3-methyl-
glutaryl-coenzyme A (HMG-CoA) restrains CMV infection in
endothelial cells.50 However, more data are needed to answer
this hypothesis.
Another interesting association observed in this study was a
lower frequency of severe infections among patients with chronic
renal failure of unknown etiology. Although there are no similar
publications in the renal transplantation literature, we can
hypothesize that this ﬁnding may be associated with minor
exposure to immunosuppressant therapy for prior diseases, as
studies published in populations with chronic renal failure have
shown this association.51
In comparison with other reports,52,53 our results show a low
mortality rate among patients requiring hospitalization because of
infection. This ﬁndingmight be explained by the strict follow-up of
all renal transplant recipients. We found an increase in the risk of
mortality among those patients who developed renal failure
secondary to diabetic nephropathy, and this association has been
previously reported by other groups.53 Also, a lower risk of death
was observed in patients with dyslipidemia, subjects known to be
under regular therapy with HMG-CoA inhibitors, drugs widely
associated with reduced cardiovascular mortality in the general
population as well as in renal transplant recipients.54
We understand that our study has some weaknesses: ﬁrst, we
could not be certain whether or not the use of statins reduced the
risk of hospitalization for infection, since not all patients with
dyslipidemia were taking lipid-lowering drugs; second, the loss of
14.2% (58 patients) of the renal transplant recipients is a ﬂaw inthis retrospective study; and third, another limitation was a poor
understanding of the true impact of the infections on renal
function.
Our data suggest that the most common infections requiring
hospitalization in this cohort were those caused by microorgan-
isms commonly associated with community-acquired infections
rather than infections classically associated with immunosuppres-
sant therapy. Our results are not intended to minimize the
microorganisms traditionally associated with the immunocom-
promised host, however the clinician should be aware of the
common community-acquired infections, as well as those infec-
tions classically associatedwith the degree of immunosuppression,
in order to reﬁne and improve the quality of medical care.
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